Stryker (SYK) Stock Forecast & Price Target

Stryker is viewed as a core MedTech holding because its broad portfolio, market-leading orthopedic robotics position, and strong capital products demand support high-single-digit to low-double-digit organic sales growth, 30bps+ operating margin expansion, and double-digit EPS growth. Management’s FY26 organic sales guidance of +8.0-9.5% y/y and adjusted diluted EPS guidance of $14.90-15.10, alongside expectations for +150 bps of EBIT margin expansion from FY26-28 and outperformance of the underlying orthopedic market by +200-300 bps in FY26, reinforce the durability of the growth profile. Continued international expansion, accretive M&A, and product launches such as MAKO 4 and MAKO RPS add further upside potential, while the company’s consistent share gains and robust free cash flow generation underpin a favorable risk/reward outlook.

Stryker is facing a tougher fundamental setup as unexpected Peripheral Vascular supply constraints following the March 11 cyber event, plus a slower recovery in Joint Replacement, are pressuring 3Q26 and could extend into 4Q26. Management now expects 2026 organic revenue growth of 8.3% to 9.3%, with the revised estimate at 8.3% and adjusted EPS near the low end of $14.95 to $15.10, while Europe’s defense-and-healthcare trade-offs, strikes, and war-related disruption are weighing especially on Hips. Competitive risk is also rising as orthopedic robotics rivals ramp programs and product-cycle maturity, slower ASC adoption, and weaker-than-expected M&A execution could limit Stryker’s growth mix and valuation support.